JUL 31, 2018 8:01 PM PDT

Two Molecules Identified For Treating Traumatic Brain Injury (TBI)

WRITTEN BY: Nouran Amin

Scientists at Rutgers University have discovered two molecules that protect nerve cells, serving as motivation to develop new drugs for brain damage. The discovery comes after 10 years of dedicated research on traumatic brain injury (TBI). The molecules were seen to promote full recovery after TBI in mouse models according to results published in the Neurobiology of Disease.

TBI, considered a major cause of disability, occurs when a sudden, violent blow or jolt, to the head leading to brain damage. According to the Centers for Disease Control and Prevention (CDC) TBI is defined as "a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury." When the brain collides with the insides of the skull, a bruising of the brain or tearing/bleeding of the nerves fibers may occur. Additionally, when the skull fractures, a piece of the skull resulting from the injury can penetrate the brain tissue. TBI can be caused by a variety of events, commonly falls, sports injuries, gunshot wounds, physical aggression, and road traffic accidents. Symptoms of TBI widely depend on the severity of the accident, the extent of the damage, and which parts of the brain are affected. In some mild cases, confusion and headaches occur. However, serious cases can result in unconsciousness, amnesia, disability, coma, and death or long-term impairment. For treatment options, all approaches are geared towards trying to prevent neurons (nerve cells) from degeneration or prompting neuron survival. This is because TBI alters neural circuits within damaged brain regions.

"The big issue with treatment after TBI is that there are no drugs that work well on patients to restore memory, and we're targeting re-connectivity of neural circuitry," explains Bonnie L. Firestein, the senior author of the research study and a professor in the Department of Cell Biology and Neuroscience at Rutgers University-New Brunswick. "That means we want our neurons to function properly and connect with other neurons. We want to allow people to retain their cognition and ability to remember and learn, so our angle is novel."

Specifically, investigators discovered a protein by the name of cypin, an enzyme that degenerates guanine; an important building block for DNA and RNA molecules in cells. The researcher’s previously proved that cypin was involved in promoting the proper shape in neurons and "keeping them happy," says Firestein. The research discovered that speeding the breakdown of guanine protects the neurons from damage as well as retaining brain function.

Using research in this study, scientists from Rutgers-New Brunswick, University of Pennsylvania, Fox Chase Chemical Diversity Center Inc. and Columbia University want to continue advancing on to the discoveries made into this study to develop drugs for patients of TBI.

Source: Neurobiology of Disease

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Probiotics Treat Alcohol-Induced Liver Injury
Alcoholic liver injury is caused by overconsumption of alcohol, something that can lead to serious diseases such as liver steatosis, liver cirrhosis and li...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
Drug Targets Against The Nipah Virus
The Nipah virus, first identified in 1998 and is transmitted from pigs and bats, has resulted in a high mortality rate killing more than half of all infect...
DEC 19, 2019
Drug Discovery & Development
DEC 19, 2019
Upcoming Psychedelic Cure for Addiction Derived from African Shrub
Every year, almost 70,000 people die from an overdose in the US. Now, a company called MindMed is testing a compound derived from ibogaine, a West African ...
DEC 27, 2019
Microbiology
DEC 27, 2019
Using a Cancer Drug to Fight Antibiotic-Resistant Pathogens
It takes a long time for a drug to be approved for use in humans; repurposing existing drugs is one way to get around that hurdle....
JAN 16, 2020
Health & Medicine
JAN 16, 2020
Babies in Africa Receive World's First Malaria Vaccine
Would you accept a vaccine that was only 40% effective? For those at risk of malaria, the answer is likely a resounding, "yes!" According to the...
FEB 20, 2020
Drug Discovery & Development
FEB 20, 2020
Antibiotics for Superbug Infections?
Antibiotics for superbug infections? A study published in the Proceedings of the National Academy of Sciences claims that a combination of compounds can ta...
Loading Comments...